Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 906913 | ISIN: US2298991090 | Ticker-Symbol: CFZ
Tradegate
14.01.25
20:49 Uhr
134,00 Euro
-1,00
-0,74 %
1-Jahres-Chart
CULLEN/FROST BANKERS INC Chart 1 Jahr
5-Tage-Chart
CULLEN/FROST BANKERS INC 5-Tage-Chart
RealtimeGeldBriefZeit
134,00135,0014.01.
134,00135,0014.01.
PR Newswire
97 Leser
Artikel bewerten:
(0)

Cullen/Frost Bankers, Inc.: Jerry Salinas, Cullen/Frost's Chief Financial Officer, To Retire At End Of This Year

Finanznachrichten News

SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Cullen/Frost Bankers, Inc. (NYSE: CFR) announced today that Jerry Salinas, group executive vice president & chief financial officer of Cullen/Frost and Frost Bank, has decided to retire at the end of 2024. Salinas has worked at Frost since 1986 in several positions, including being named bank and corporate controller in 1989 and treasurer in 1997. He became senior executive vice president and treasurer in 2001 and was named to his current position in 2015.

"If you think of any major initiative that the company has undertaken in the past four decades -acquisitions, major transactions, our expansion projects - Jerry played an important role in all of them," said Phil Green, Cullen/Frost Chairman and CEO. "In addition, Jerry has been a trusted adviser and a good friend. I would like everyone at Frost to join me in thanking him and congratulating him on his well-deserved retirement."

Salinas said he was grateful for the chance to spend his career at Frost. "It has been a great experience to help the company grow and prosper over the years, and it has been a blessing to have spent my career at an organization with such a great culture and with core values that mirror my personal values," he said. "I have worked for Phil my entire career at Frost, and I am grateful for his mentorship, trust and friendship over the years. I will miss the relationships that I have developed here and will remember them fondly as I look forward to the next phase of my life."

Effective immediately, Frost's San Antonio Region President Dan Geddes will step down from his current position as he transitions to assume the role of chief financial officer on Jan. 1, 2025. Geddes will join Frost's executive leadership team in the interim.

"Dan is a 27-year Frost commercial banker who has a broad experience in our company, having led the successful execution of our Houston expansion as well as successfully leading our largest region in our headquarters market of San Antonio," Green said. "At Frost, we expect our CFO to also act as a kind of chief integrity officer, which Jerry did admirably. Dan will do a fantastic job continuing that tradition."

Longtime San Antonio commercial banker Clay Jones has been named the new San Antonio region president, effective immediately. Matt Henson, an executive vice president with 21 years of experience in Frost's accounting division, will assume the role of chief accounting officer on Jan. 1, 2025.

About Frost:
Frost is the banking, investments and insurance subsidiary of Cullen/Frost Bankers, Inc. (NYSE: CFR), a financial holding company with $49.5 billion in assets at March 31, 2024. One of the 50 largest U.S. banks by asset size, Frost provides a full range of banking, investments and insurance services to businesses and individuals in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley and San Antonio regions. Founded in 1868, Frost has helped Texans with their financial needs during three centuries. For more information, visit www.frostbank.com.

AB Mendez
Investor Relations
210-220-5234
or
Bill Day
Media Relations
210-220-5427

SOURCE Cullen/Frost Bankers, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.